Intravenous (IV), jet or infusion. The dose of the drug is set individually, depending on the severity of the disease, the localization of the infection, the type of pathogen and its sensitivity to the drug, as well as the age of the patient and kidney function.
The maximum daily dose is 6 g, the maximum daily dose for adults
of patients with cystic fibrosis is 9 g.
Adults and children over 12 years of age: 1-6 g / day in 2 or 3 injections.
Usually 1 g every 8 hours or 2 g every 12 hours.
In severe disease, especially in patients with immunodeficiency (including patients with neutropenia), 2 g every 8 hours or 12 hours, or 3 g every 12 hours.
For infections of the urinary tract and infections of the lung current, 0.5 g or 1 g every 12 hours.
For the treatment of infectious complications in cystic fibrosis caused by Pseudomonas aeruginosa, 100-150 mg / kg / day in 3 injections.
In operations on the prostate gland - 1 g during an introductory anesthesia, the second dose is administered after removal of the catheter.
Children older than 2 months and up to 12 years: 30-100 mg / kg / day in 2-3 administration.
Children with immunodeficiency, cystic fibrosis and meningitis - up to 150 mg / kg / day
(maximum - 6 g / day) in 3 injections.
Newborns and children from 28 days to 2 months: 25-60 mg / kg / day in 2 injections.
Older patients: the recommended dose is no more than 3 g / day, especially in patients older than 80 years.
Patients with renal insufficiency: ceftazidime is excreted by the kidneys unchanged, so patients with renal dysfunction should be reduced the dose of ceftazidime. The initial dose is 1 g, the maintenance dose is selected depending on the rate of glomerular filtration.
Supportive doses of ceftazidime in renal failure
| Creatinine clearance (ml / min) | Concentration of creatinine in blood plasma, μmol / l (mg / dL) | Recommended single doses (g) | Frequency of drug administration |
| >50 | < 150 (<1,7) | Standard doses |
| 50-31 | 150-200(1,7-2,3) | 1,0 | every 12 hours |
| 30-16 | 200-350 (2,3-4,0) | 1,0 | every 24 hours |
| 15-6 | 350-500 (4,0-5,6) | 0,5 | every 24 hours |
| <5 | > 500 (>5,6) | 0,5 | every 48 hours |
Patients with infections of severe course can increase the recommended single dose by 50% or the frequency of administration of the drug. In such patients should monitor the concentration of ceftazidime in blood plasma (should not exceed 40 mg / l).
The drug can be used in children with impaired renal function, while the creatinine clearance is calculated in accordance with the ideal mass or surface area of the body.
Hemodialysis. During hemodialysis, the elimination half-life is 3-5 hours.
After each hemodialysis session, maintenance doses of ceftazidime in
according to the table above.
Peritoneal dialysis. Ceftazidime can be used during peritoneal dialysis. Such patients are injected with 0.5 g of the drug every 24 hours.
For patients with renal insufficiency in the intensive care unit
therapy for continuous hemodialysis using an arteriovenous shunt and for patients on high-speed haemofiltration, the recommended dose is 1 g / day daily (in one or more administrations).
For patients who are on hemofiltration at a low rate, the same doses of the drug are recommended, as in the case of impaired renal function.
Patients on hemodialysis or haemofiltration using a venovenous shunt are recommended doses shown in the table.
Doses of ceftazidime in patients on hemofiltration using a veno-venous shunt.
| Creatinine clearance (ml / ml) | Maintenance dose (mg) depending on the rate of ultrafiltration (ml / min) * |
| 5 | 16,7 | 33,3 | 50 |
| 0 | 250 | 250 | 500 | 500 |
| 5 | 250 | 250 | 500 | 500 |
| 10 | 250 | 500 | 500 | 750 |
| 15 | 250 | 500 | 500 | 750 |
| 20 | 500 | 500 | 500 | 750 |
* The maintenance dose is given every 12 hours.
Doses of ceftazidime in patients on continuous hemodialysis using a veno-venous shunt.
| Creatinine clearance (ml / min) | Maintenance dose (mg) depending on the rate of dialysis * |
| 1.0 l / h | 2.0 l / h |
| Rate of ultrafiltration (l / h) | Rate of ultrafiltration (l / h) |
| 0,5 | 1,0 | 2,0 | 0.5 | 1.0 | 2.0 |
| 0 | 500 | 500 | 500 | 500 | 500 | 750 |
| 5 | 500 | 500 | 750 | 500 | 500 | 750 |
| 10 | 500 | 500 | 750 | 500 | 750 | 1000 |
| 15 | 500 | 750 | 750 | 750 | 750 | 1000 |
| 20 | 750 | 750 | 1000 | 750 | 750 | 1000 |
* The maintenance dose is given every 12 hours.
The duration of treatment with ceftazidime is 7-14 days. In infections caused by Pseuchmonas aeruginosa (pneumonia, infectious complications of cystic fibrosis, meningitis) treatment course can be increased up to 21 days. Treatment with ceftazidime, like any other antibacterial therapy, should continue for at least 48-72 hours, after reducing the symptoms of acute inflammation and normalizing the temperature.
Preparation of a solution for intravenous administration.
In the solution of the preparation, small bubbles of carbon dioxide may be present, which does not affect the effectiveness of the preparation. Do not use sodium bicarbonate solution as a solvent.
| The amount of ceftazidime in the vial | Method of administration | Amount of solvent, ml | Approximate concentration, mg / ml |
| 2 grams | Intravenously, intravenously | 10 | 170 |
| 2 grams | Intravenous infusion | 50 | 40 |
For intravenous bolus administration, the contents of the vial are dissolved in 10 ml of a solvent. For intravenous drip introduction, the resulting solution of the preparation is further diluted in 50-100 ml of solvent ("secondary" dilution). As a solvent, water for injections or compatible infusion solutions.
Ceftazidime in a concentration of 1 to 40 mg / ml is compatible with infusion solutions: 0
, 9% sodium chloride solution, Hartmann solution, 5% and 10% dextrose solutions, 0.225% sodium chloride solution and 5% dextrose solution, 0.45% sodium chloride solution and 5% dextrose solution, 0.9% sodium chloride solution and 5% dextrose solution, 0.18% sodium chloride solution and 4% dextrose solution, 10% Dextran 40 solution in 0.9% sodium chloride solution or 5% dextrose solution, 6% Dextran 70 solution in 0.9% sodium chloride solution or in a 5% solution of dextrose,a solution of metronidazole 5 mg / ml.
In concentrations from 0.05 to 0.25 mg / ml ceftazidime compatible with the solution for intraperitoneal dialysis (lactate).
Both components remain active if ceftazidime in a concentration of 4 mg / ml is added to the following solutions: hydrocortisone 1 mg / ml in 0.9% solution of sodium chloride or 5% solution of dextrose; cefuroxime 3 mg / ml in 0.9% solution of sodium chloride; cloxacillin 4 mg / ml in 0.9% sodium chloride solution; heparin 10 MP / ml or 50 IU / ml in a 0.9% solution of sodium chloride; potassium chloride 10 mEq / L or 40 mEq / L in a 0.9% solution of sodium chloride.
Use only freshly prepared solution!
Light yellowing of the solution does not affect the efficiency.